The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study.
 
Romualdo Barroso-Sousa
Consulting or Advisory Role - Lilly
Speakers' Bureau - Roche
 
Ines Maria Vaz Duarte Luis
Honoraria - AstraZeneca; Kephren; Novartis
Consulting or Advisory Role - Ipsen
 
Antonio Di Meglio
No Relationships to Disclose
 
Jiani Hu
No Relationships to Disclose
 
Rebecca Rees
No Relationships to Disclose
 
Natalie Faye Sinclair
No Relationships to Disclose
 
Lindsey Milisits
No Relationships to Disclose
 
Jose Pablo Leone
Research Funding - Kazia Therapeutics (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Michael Constantine
No Relationships to Disclose
 
Meredith Gail Faggen
No Relationships to Disclose
 
Frederick Briccetti
No Relationships to Disclose
 
Caroline Cole Block
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Pfizer (Inst)
 
Ann H. Partridge
No Relationships to Disclose
 
Harold J. Burstein
No Relationships to Disclose
 
Adrienne Gropper Waks
No Relationships to Disclose
 
Lorenzo Trippa
No Relationships to Disclose
 
Sara M. Tolaney
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Celldex; Eisai; Genentech; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology; Sanofi; Tesaro
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
 
Michael J. Hassett
No Relationships to Disclose
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Carrick Therapeutics; Genentech/Roche; GlaxoSmithKline; InfiniteMD; Jounce Therapeutics; Jounce Therapeutics; Lilly; Tesaro
Consulting or Advisory Role - InfiniteMD; Leap Therapeutics
Research Funding - Genentech (Inst)
 
Nancy U. Lin
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Novartis; Puma Biotechnology; Seagen
Research Funding - Genentech; Novartis; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases